Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study

(2011) J. D. Lewis et al.   DIABETES CARE

A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes

(2011) A. P. S. Kong et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

(2011) Kim Henriksen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Apolipoprotein E in Alzheimer's disease and other neurological disorders

(2011) Philip B Verghese et al.   LANCET NEUROLOGY

Rosiglitazone Revisited

(2010) Steven E. Nissen et al.   ARCHIVES OF INTERNAL MEDICINE

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2010) Michael Gold et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia

(2009) Suzanne Craft   ARCHIVES OF NEUROLOGY

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease

(2009) Tomohiko Sato et al.   NEUROBIOLOGY OF AGING

Peroxisome Proliferator-Activated Receptor-γ-Mediated Positive Energy Balance in the Rat Is Associated with Reduced Sympathetic Drive to Adipose Tissues and Thyroid Status

(2008) William T. Festuccia et al.   ENDOCRINOLOGY

PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease

(2008) Gary Landreth et al.   Neurotherapeutics